Hood River Capital Management’s Beam Therapeutics BEAM Stock Holding History

Hood River Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-251,633	Closed	-$8.04M	–	126
2023 Q2	$8.04M	Buy	251,633 +14,026	+6%	+$455K	0.24%	83
2023 Q1	$7.28M	Buy	237,607 +6,210	+3%	+$245K	0.24%	78
2022 Q4	$9.05M	Buy	231,397 +1,418	+0.6%	+$63.5K	0.33%	78
2022 Q3	$11M	Buy	+229,979	New	+$13.1M	0.42%	72

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Hood River Capital Management's BEAM Position: Q3 2023 in Review

Hood River Capital Management sold out of Beam Therapeutics (BEAM) in Q3 2023, closing a stake of 251,633 shares — an estimated $8.04M sold.

Hood River Capital Management first reported a position in BEAM in Q3 2022 and held it in 4 quarters. The position peaked at $11M in Q3 2022. 194 funds tracked by Wall St. Rank hold BEAM as of Q3 2023.

Hood River Capital Management reported no remaining Beam Therapeutics position as of Q3 2023 after selling out during the quarter.
Hood River Capital Management sold 251,633 Beam Therapeutics shares in Q3 2023, an estimated $8.04M.
Hood River Capital Management first reported a position in Beam Therapeutics in Q3 2022 and held it in 4 quarters.
Hood River Capital Management's Beam Therapeutics position peaked at $11M in Q3 2022.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2023.

Based on Hood River Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.